| Sep 28 |
Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study
|
| Sep 28 |
2 Excellent Dividend Stocks to Buy With Less Than $200
|
| Sep 27 |
J&J, Legend report Carvykti cut death risk by 45% in multiple myeloma study
|
| Sep 27 |
J&J releases encouraging data on Talvey combination therapies
|
| Sep 27 |
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
|
| Sep 27 |
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
|
| Sep 27 |
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
|
| Sep 27 |
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
|
| Sep 27 |
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
|
| Sep 27 |
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
|
